Outcomes of light‐chain amyloidosis patients treated with first‐line bortezomib: a collaborative retrospective multicenter assessment
Moshe E. Gatt(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Svetlana Trestman, Izhar Hardan(Meir Medical Center), Evgeni Chubar(Emek Medical Center), Najib Dally(Rebecca Sieff Hospital), Mouna Ballan‐Haj(Carmel Medical Center), Tamar Tadmor(Bnai Zion Medical Center), Shay Yeganeh(Poriya Medical Center), Julia Jakubinsky(Rambam Health Care Campus), Hila Magen(Sheba Medical Center), Paulina Patachenco(Wolfson Medical Center), Eli Muchtar(Mayo Clinic), Yaël C. Cohen(Sheba Medical Center), Irit Avivi(Tel Aviv Sourasky Medical Center), Olga Shevetz, Celia Suriu(Western Galilee Hospital)
Cited by 16
Related Papers
Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis
|Antimicrobial Agents and Chemotherapy|2010|727
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
|Blood|2017|344
Systemic amyloidosis from A (AA) to T (ATTR): a review
|Journal of Internal Medicine|2020|329
Restrictive Cardiomyopathy
|Circulation Research|2017|320